| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total operating expenses | 5,782 | 7,503 | 12,601 | 12,418 |
| Loss from operations | -5,692 | -7,503 | -12,601 | -12,418 |
| Interest income - net | 561 | 625 | 1,033 | 1,065 |
| Total other income | 561 | 625 | 1,033 | 1,065 |
| Net loss | -5,131 | -6,878 | -11,568 | -11,353 |
| Net loss per common share basic (in dollars per share) | -0.16 | -0.22 | -0.37 | -0.38 |
| Net loss per common share diluted (in dollars per share) | -0.16 | -0.22 | -0.37 | -0.38 |
| Weighted average common shares outstanding basic (in shares) | 31,195,891 | 31,195,891 | 31,071,297 | 30,103,063 |
| Weighted average common shares outstanding diluted (in shares) | 31,195,891 | 31,195,891 | 31,071,297 | 30,103,063 |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)